Should You Invest in This Dividend King on the Dip?
Earnings season is underway, and it has already made some winners and losers. One company that seems to be in the latter category is Johnson & Johnson (NYSE:JNJ) . The healthcare giant had been performing well this year, but its shares dipped significantly after it reported its third-quarter financial results. Is this a buying opportunity? Or should investors run for the hills? Let's find out. Image source: The Motley Fool. At first glance, Johnson & Johnson's latest quarterly update looked robust. In fact, it was a beat-and-raise quarter for the healthcare leader . Revenue came in at $25.4 billion, 5.9% higher than the year-ago period. Johnson & Johnson's adjusted earnings per share (EPS) were $2.59, down 7.5% compared to the prior-year quarter. The decline was mostly due to the impact of acquisitions and was expected, so it's nothing investors should worry about too much. Continue reading